Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records

Non-communicable diseases (NCDs) are chronic diseases that are not transmitted from person to person. Each year 41 million people die due to NCDs. From 1995 to 2007 (12 years), Indonesia has undergone an epidemiological transition in which deaths from NCDs increased, while deaths due to infectious diseases declined. Prevalence of NCDs in the Special Region of Yogyakarta (DIY) has also continued to increase in 2007-2013. We conducted research to obtain a description of body mass index, blood pressure, and random blood glucose in Jaten, Sinduadi, Mlati, Sleman, DIY as early screening for NCDs. This research was a retrospective study using data obtained from the records from a medical check-up done in a community service program on August 19, 2018. Data obtained included age, height, weight, blood pressure, and random blood glucose levels. A total of 96 people were screened. Most (72.9%) participants were adults (aged ≥ 20 years to ≤ 59 years). Results of the screening showed that 43% of participants were overweight or obese, 70% had hypertension, and 5.7% had the random blood glucose of ≥ 200 mg/dL. The percentage of obesity, hypertension, and diabetes mellitus in Jaten Hamlet are relatively high, indicating a need for long term education and intervention to decrease NCDs prevalence and complications.

Download Full-text

Photosensitivity with Angiotensin II Receptor Blockers: A Retrospective Study Using Data from VigiBase®

Drug Safety ◽

10.1007/s40264-015-0323-7 ◽

2015 ◽

Vol 38 (10) ◽

pp. 889-894 ◽

Cited By ~ 10

Author(s):

Ermelinda Viola ◽

Anna Coggiola Pittoni ◽

Agnes Drahos ◽

Ugo Moretti ◽

Anita Conforti

Keyword(s):

Retrospective Study ◽

Angiotensin Ii ◽

Angiotensin Ii Receptor Blockers ◽

Angiotensin Ii Receptor ◽

Receptor Blockers ◽

Using Data

Download Full-text

Intraoperative Changes in Blood Glucose Levels Increase the Risk of Death in Cardiac Surgery

Aktuelle Ernährungsmedizin ◽

10.1055/s-2006-946735 ◽

2006 ◽

Vol 31 (03) ◽

Author(s):

H Hager ◽

E Giorni ◽

A Felli ◽

B Mora ◽

M Hiesmayr ◽

...

Keyword(s):

Cardiac Surgery ◽

Blood Glucose ◽

Glucose Levels ◽

Risk Of Death ◽

Blood Glucose Levels

Download Full-text

The value of blood glucose levels for the parameters of nocturnal sleep for patients with type 1 diabetes

Endocrine Abstracts ◽

10.1530/endoabs.49.ep541 ◽

2017 ◽

Author(s):

Ina Darashkevich ◽

Tatiana Mochort ◽

Lola Niconova ◽

Serhey Tishkovsky

Keyword(s):

Type 1 Diabetes ◽

Blood Glucose ◽

Nocturnal Sleep ◽

Glucose Levels ◽

Blood Glucose Levels

Download Full-text

The Impact of Angiotensin-II Receptor Blockers on Cardiovascular Events in Hypertensive Patients – Evidence from Real-life Databases

European Cardiology Review ◽

10.15420/ecr.2010.6.3.33 ◽

2010 ◽

Vol 6 (3) ◽

pp. 33

Author(s):

Robert J Petrella ◽

Keyword(s):

Angiotensin Ii ◽

Antihypertensive Drugs ◽

Real Life ◽

Angiotensin Ii Receptor Blockers ◽

Angiotensin Ii Receptor ◽

Real World Setting ◽

Actual Experience ◽

Receptor Blockers ◽

Randomised Controlled ◽

The Impact

It is widely recognised that hypertension is a major risk factor for the development of future cardiovascular (CV) events, which in turn are a major cause of morbidity and mortality. Blood pressure (BP) control with antihypertensive drugs has been shown to reduce the risk of CV events. Angiotensin-II receptor blockers (ARBs) are one such class of antihypertensive drugs and randomised controlled trials (RCTs) have shown ARB-based therapies to have effective BP-lowering properties. However, data obtained under these tightly controlled settings do not necessarily reflect actual experience in clinical practice. Real-life databases may offer alternative information that reflects an uncontrolled real-world setting and complements and expands on the findings of clinical trials. Recent analyses of practice-based real-life databases have shown ARB-based therapies to be associated with better persistence and adherence rates and with superior BP control than non-ARB-based therapies. Analyses of real-life databases also suggest that ARB-based therapies may be associated with a lower risk of CV events than other antihypertensive-drug-based therapies.

Download Full-text

A Review of Angiotensin Receptor Blocker-based Therapies at all Levels of Cardiovascular Risk

European Cardiology Review ◽

10.15420/ecr.2011.7.4.254 ◽

2011 ◽

Vol 7 (4) ◽

pp. 254 ◽

Cited By ~ 1

Author(s):

Giuliano Tocci ◽

Lorenzo Castello ◽

Massimo Volpe ◽

◽

...

Keyword(s):

Angiotensin Ii ◽

Ventricular Hypertrophy ◽

Renin Angiotensin System ◽

Left Ventricular ◽

Clinical Settings ◽

Angiotensin Ii Receptor ◽

Angiotensin System ◽

Receptor Blockers ◽

Artery Disease

The renin–angiotensin system (RAS) has a key role in the maintenance of cardiovascular homeostasis, and water and electrolyte metabolism in healthy subjects, as well as in several diseases including hypertension, left ventricular hypertrophy and dysfunction, coronary artery disease, renal disease and congestive heart failure. These conditions are all characterised by abnormal production and activity of angiotensin II, which represents the final effector of the RAS. Over the last few decades, accumulating evidence has demonstrated that antihypertensive therapy based on angiotensin II receptor blockers (ARBs) has a major role in the selective antagonism of the main pathological activities of angiotensin II. Significant efforts have been made to demonstrate that blocking the angiotensin II receptor type 1 (AT1) subtype receptors through ARB-based therapy results in proven benefits in different clinical settings. In this review, we discuss the main benefits of antihypertensive strategies based on ARBs in terms of their efficacy, safety and tolerability.

Download Full-text